Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
SWITCH Study
STENTRODE WITH THOUGHT CONTROLLED DIGITAL SWITCH: An early feasibility study (EFS) of the safety of the StentrodeTM device in participants with loss of motor function due to paralysis from spinal cord injury, motor neuron disease, stroke, muscular dystrophy or loss of limbs.
Research has shown that in individuals with neurological conditions, brain signals can be recorded using electrical sensors implanted on to the brain. These signals could be used by the individuals to control assistive technology (e.g. spelling devices) that help with daily life, just by thinking. However, implanting these electrical sensors often requires open brain surgery.
A new medical device and surgical technique has been developed, which allows implantation of the electrical sensors without open brain surgery. The device, called Stentrodeâ„¢, is a small metallic mesh tube (stent), with electrode contacts (small metal disks) within the stent structure. It can be placed inside a blood vessel of the brain located in the motor cortex. This does not involve open brain surgery.
The purpose of this research is to evaluate the safety of the Stentrodeâ„¢ device in humans. This is an experimental device. This research will be the first of its kind to be performed in humans and may help find safer, more effective ways to introduce/implant electrical sensors in patients. This could foster the development of user friendly biotechnology for patients with neurological conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| single | Other | Implantation of Stentrode device |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stentrode | Device | Implantation of Stentrode device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-Related Adverse Events | Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 | 12 month post implant |
| Measure | Description | Time Frame |
|---|---|---|
| High fidelity and stable signals over 12 months |
| 36 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Is unwilling to comply with all procedures relating to study
Based on the doctors opinion, has unrealistic expectations regarding the possible benefits, risks and limitations associated with the implantation or surgical procedures
Has dementia or cognitive impairment sufficient to impair capacity to provide informed consent or which could impact ability to comply with investigational requirements (eg: MMSE <24, ECAS or other determination made by Investigator)
For MND participants, has NOT had a formal capacity assessment by a professional with experience in capacity assessment (psychiatrist, neurologist, psychologist) within 90 days of Screen1 visit, which assesses capacity to consent and excludes Frontotemporal dementia
Has a history of substance abuse within the preceding two (2) years
Chronic oral or intravenous steroids or immunosuppressive therapy or other therapy/clinical condition that severely reduces immunity Has been hospitalized for a psychiatric condition with the preceding two (2) years or has had a history of psychosis within the preceding two (2) years
Has a contraindication to magnetic resonance imaging (MRI)
Has an active implanted stimulation device (eg: pacemaker, deep brain stimulator, spinal cord stimulator)
Is deemed unsuitable by a specialist anaesthesiologist or respiratory physician to undergo a general anaesthetic
Has findings on MRV deemed incompatible, by an experienced neurointerventionalist, with device implantation in the SSS [eg: isolated dominant, superior anastomotic vein (vein of Trolard)]
Has a contraindication to angiographic imaging, including chronic kidney injury (CKI -eGFR < 60mls/min)
Has known allergy to contrast media
Has any bleeding disorders (tests required if clinical status unknown) or is resistant to aspirin and/or clopidogrel or has any contraindication that precludes antithrombotic treatment
Has an allergy to any materials included in the implanted device
Has a history of Deep Vein Thrombosis (DVT) or on hormone therapy (eg: HRT)
Any serious disease or disorder that in the opinion of the Investigator, could seriously affect ability to participate in the study
Does not have a family member/caregiver (or equivalent) who can be present during the consent process and support all study visits
Has had any of the following neuropathologies;
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Thomas Oxley | University of Melbourne and Synchron | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Melbourne Hospital | Melbourne | Victoria | 3050 | Australia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36622685 | Derived | Mitchell P, Lee SCM, Yoo PE, Morokoff A, Sharma RP, Williams DL, MacIsaac C, Howard ME, Irving L, Vrljic I, Williams C, Bush S, Balabanski AH, Drummond KJ, Desmond P, Weber D, Denison T, Mathers S, O'Brien TJ, Mocco J, Grayden DB, Liebeskind DS, Opie NL, Oxley TJ, Campbell BCV. Assessment of Safety of a Fully Implanted Endovascular Brain-Computer Interface for Severe Paralysis in 4 Patients: The Stentrode With Thought-Controlled Digital Switch (SWITCH) Study. JAMA Neurol. 2023 Mar 1;80(3):270-278. doi: 10.1001/jamaneurol.2022.4847. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Insertion of Stentrode TM device
Not provided
Not provided
Not provided
Not provided